Date:3/5/2009

--------------------------------------------------------------------- (5,535) (4,582) ------------- ------------- e. Selling, general and administrative adjustments: --------------------------------------------------------------------- Year-ended Year-ended Dec 31, 2008 Dec 31, 2007 ------------- ------------- Stock-based compensation (1,641) (2,924) Termination and reorganization costs (6,983) (8,365) Litigation expenses relating to defending intellectual property claims (2,670) (4,931) Non-recurring financing fees (665) - Non-recurring supply / distribution agreement termination costs - (250) --------------------------------------------------------------------- (11,959) (16,470) ------------- ------------- f. Amortization of acquisition-related intangible assets and medical technologies. g. Non-recurring in-process research and development expense relating to payments made to licensors and collaborators. h. Foreign exchange fluctuations on foreign currency net monetary assets. i. Realized loss on disposition of assets and unrealized loss on write- down of an intangible asset. In 2007, write-off of uncollectible receivable and write-off of certain capitalized costs, net of gain realized on recovery of investments. j. Amortization of deferred financing costs. k. Write-down of other def
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study